Richard Ramko is a partner in Ernst & Young's South Florida practice, primarily serving publicly-held and emerging growth companies in the Health Sciences, Biotech and Technology industries.
Ramko has extensive experience serving large, publicly-held companies as well as newly formed start-ups and venture-backed enterprises. Richard has 15 years of experience, including 13 years in public accounting and 2 years in executive level financial positions in private industry and is a certified public accountant in Florida and Tennessee. Some of his current clients include Andrx Corporation, Nabi Biopharmaceuticals, Stiefel Laboratories and SFBC International.
In 2005, biotech stocks performed strongly in contrast to the relatively poor performance of 2004. The market capitalization of the US biotechnology sector outperformed the DOW and the NASDAQ climbing by about 22% in 2005 compared to 11% in 2004. This increase was fueled in large part by increases...(Full transcript available to logged in subscribers.).
Register & Subscribe
Login
